A wave of new drugs have revolutionised the weight loss industry. Now, getting your hands on one popular medication could get ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... which is already seeing sales rocket on the back of its use as Ozempic for diabetes, Wegovy for obesity, and label extensions for both brands ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...